NCBiotech News

Twenty-nine technology companies across North Carolina – about half of them working in the life sciences – have received One North Carolina program grants totaling $1.5 million.

Frost & Sullivan has named Durham’s 410 Medical as the 2021 Entrepreneurial Company of the Year in the global fluid resuscitation devices industry.

Pairwise, an agricultural biotechnology company that applies gene-editing techniques to food crops, has raised $90 million in funding as it eyes commercialization of its first product next year.

The North Carolina Biotechnology Center awarded 17 grants and loans totaling more than $1.4 million to universities, biosciences companies and other entities in the second quarter of its fiscal year.

Charles River Laboratories, a large Massachusetts-headquartered contract research organization, is expanding its footprint in North Carolina.

Novozymes, the world’s largest industrial biotechnology company with U.S. headquarters in North Carolina, is branching out into “pest control agritechnology” through a development agreement with FMC.

Durham medical device company EmitBio has reported positive clinical trial results for its initial 31-patient test of its device that works like a flashlight to shine safe, visible LED light into the throat to attack bad bugs, including SARS-CoV-2, the coronavirus causing COVID-19.

A year-old RTP nonprofit, Med Aditus International, founded by retired UNC pharmacy prof Dhiren R. Thakker, Ph.D., is about to launch a game-changing pharmaceutical manufacturing and training initiative to provide affordable, high-quality medicines in sub-Saharan Africa.

Durham's Bioventus has filed regulatory paperwork outlining a preliminary $100 million target for a proposed initial public stock offering

Belgian food and crop protection company Biotalys NV, with U.S. headquarters in NCBiotech's Landing Pad offices, has just submitted its first product for U.S. Environmental Protection Agency approval.

Durham's Precision Biosciences has received FDA approval to advance its new drug for patients with relapsed/refractory non-Hodgkin Lymphoma.

Durham-based Chimerix priced the stock offering late Wednesday, selling more than 11.7 million shares for $8.50 apiece to raise $100 million that can help bring lead drugs to FDA approval.

Target RWE, a clinical data company based in Durham, has acquired a neighboring software analysis and services company, NoviSci, and scored an investment from California biotech pioneer Amgen.

Global biotherapeutics giant Grifols will soon start a clinical trial for what could become the second approved treatment for COVID-19.

Atsena Therapeutics is a Durham clinical-stage gene therapy company with $63M in the bank so far to propel its mission to reverse and prevent blindness.